Form 4: Ionis Pharma CSO Sells Shares After PRSU Vesting

Ionis Pharmaceuticals' Chief Scientific Officer, C. Frank Bennett, acquired 11,421 shares from vested performance-based restricted stock units and subsequently sold 5,885 shares.

Summary

• C. Frank Bennett, Executive Vice President and Chief Scientific Officer of Ionis Pharmaceuticals Inc. (IONS), acquired 11,421 shares of Common Stock.
• These shares were earned upon the vesting of performance-based restricted stock units (PRSUs) granted on January 18, 2023.
• The Compensation Committee certified achievement of the pre-established performance goal, based on the Issuer's relative total shareholder return compared to a peer group, at a level resulting in a vest of 167.27% of target shares.
• Bennett subsequently sold 5,885 shares of Common Stock on January 30, 2026, at a weighted average price of $82.9466 per share.
• Following these transactions, Bennett directly beneficially owns 100,293 shares of Common Stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as moderately positive due to the strong performance indicated by the high PRSU vesting, despite the executive's subsequent share sale, which is a common practice for tax and diversification purposes.

Positives

• The performance-based restricted stock units (PRSUs) vested at 167.27% of target shares, indicating strong performance relative to the company's peer group.
• The high vesting percentage suggests the company's total shareholder return significantly outperformed its competitors during the performance period.

Negatives

• A key executive, C. Frank Bennett, sold 5,885 shares of common stock, which reduces insider ownership.

Future Outlook

NA

Management Comments

• The Compensation Committee certified achievement of the pre-established performance goal based on the Issuer's relative total shareholder return as compared to a peer group of companies at a level resulting in a vest of 167.27% of target shares.

Industry Context

StockSavvy.ai notes that executive share sales following equity vesting are a common practice for tax planning and portfolio diversification. The high PRSU vesting percentage suggests strong relative performance for Ionis Pharmaceuticals within its peer group, which is a positive indicator for the company's operational and strategic execution in the biotechnology sector.

Comparison to Industry Standards

• The 167.27% vesting of performance-based restricted stock units (PRSUs) indicates that Ionis Pharmaceuticals significantly outperformed its peer group in terms of relative total shareholder return during the performance period. This level of achievement is substantially higher than a typical 100% target vesting, suggesting superior performance compared to many companies in the biotechnology and pharmaceutical industries.

Stakeholder Impact

• Shareholders: The high PRSU vesting suggests strong company performance relative to peers, which is generally positive for shareholders. The executive's sale of shares is a common event and not necessarily a negative signal, but it reduces insider ownership slightly.
• Employees: The performance-based compensation structure aligns executive incentives with company performance, potentially motivating high achievement.

Key Dates

Recommendation

The filing details a routine insider transaction where an executive sold shares after a significant vesting event. While the high PRSU vesting percentage indicates strong underlying company performance relative to its peers, the sale itself does not provide a new catalyst for a strong 'buy' or 'sell' recommendation. The information is largely consistent with normal executive compensation practices.

Keywords

IONIS PHARMACEUTICALS, IONS, C. Frank Bennett, Form 4, insider transaction, stock sale, PRSU, restricted stock units, executive compensation